Compound ID	CDAMM00339
Common name	Mitragynine
IUPAC name	methyl (E)-2-[(2S,3S,12bS)-3-ethyl-8-methoxy-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizin-2-yl]-3-methoxyprop-2-enoate
Molecular formula	C₂₃H₃₀N₂O₄

Experimental data

Retention time	35.912
Adduct	[M+NH4]+
Actual mz	416.251
Theoretical mz	416.254
Error	7.87
Ionizaton mode	Positive
Instrument type	LC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score	7.23

Identifiers and class information

Inchi key	LELBFTMXCIIKKX-BVJUKVBNNA-N
Smiles	O=C(OC)C(=COC)C1CC2C=3NC=4C=CC=C(OC)C4C3CCN2CC1CC
Superclass	Alkaloids and derivatives
Class	Corynanthean-type alkaloids

Plant source

Pedalium murex L.

Plumbago zeylanica Linn.

Baliospermum solanifolium (Burm.) Suresh

External sources

HMDB ID	HMDB0041933
KNApSAcK ID	C00001751
FooDB ID
DrugBank ID
ChEBI ID	CHEBI:6956
Pubchem Compound ID	3034396
PlantCyc ID
UNPD ID	UNPD100093
Coconut ID
LipidMAPS ID
NANPDB ID

Pharmacokinetic properties

Number of descriptor values(#stars)	1
Number of non-conjugated amine groups (#amine)	1
Number of amidine and guanidine groups (#amidine)	0
Number of carboxylic acid groups (#acid)	0
Number of non-conjugated amide groups (#amide)	0
Number of rotatable bonds (#rotor)	5
Number of reactive functional groups (#rtvFG)	1
Predicted central nervous system activity (CNS)	1
Molecular weight (mol_MW)	398.501
Computed dipole moment(dipole)	6.911
Total solvent accessible surface area (SASA)	735.428
Hydrophobic component of SASA (FOSA)	534.69
Hydrophilic component of SASA (FISA)	55.732
Pie component of the SASA (PISA)	145.005
Weakly polar component of the SASA (WPSA)	0
Total solvent accesible volume (volume)	1322.6
Number of hydrogen bond donors (donorHB)	1
Number of hydrogen bond acceptors (accptHB)	6.45
Free energy of solvation of dipole (dip^2/V)	0.03611
Index of cohesive interaction in solids (ACxDN^.5/SA)	0.0087704
Globularity descriptor (glob)	0.79234
Predicted polarizability in cubic angstroms (QPpolrz)	44.951
Predicted hexadecane/gas partition coefficient (QPlogPC16)	12.218
Predicted octanol/gas partition coefficient (QPlogPoct)	19.704
Predicted water/gas partition coefficient (QPlogPw)	9.569
Predicted octanol/water partition coefficient (QPlogPo/w)	4.129
Predicted aqueous solubility (QPlogS)	-5.218
Conformation-independent predicted aqueous solubility (CIQPlogS)	-4.253
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)	-6.31
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)	731.627
Predicted brain/blood partition coefficient (QPlogBB)	0.069
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)	390.43
Predicted skin permeability, log Kp (QPlogKp)	-3.618
PM3 calculated ionization potential (IP(ev))	7.676
PM3 calculated electron affinity (EA(eV))	-0.007
Number of likely metabolic reactions (#metab)	5
Prediction of binding to human serum albumin (QPlogKhsa)	0.715
Predicted qualitative human oral absorption (HumanOralAbsorption)	3
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)	100
Solvent-accessible surface area of fluorine atoms (SAFluorine)	0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)	0
Van der Waals surface area (PSA)	62.884
Number of nitrogen and oxygen atoms (#NandO)	6
Number of violations of Lipinski’s rule of five (RuleOfFive)	0
Number of violations of Jorgensen’s rule of three (RuleOfThree)	0

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID	Gene name	Target name	TTD_ID	Prediction source
P08173	CHRM4	Muscarinic acetylcholine receptor M4	T20709	SEA
Q05940	SLC18A2	Synaptic vesicular amine transporter (by homology)	T48873	SEA
P18825	ADRA2C	Adrenergic receptor alpha-2	T01777	SEA
P06276	BCHE	Butyrylcholinesterase	T99799	SwissTargetPrediction
P41143	OPRD1	Delta opioid receptor	T58992	SwissTargetPrediction
P48039	MTNR1A	Melatonin receptor 1A	T97613	SEA
O75884	RBBP9	Putative hydrolase RBBP9	T12084	SEA

Target associated diseases

TTD_ID	Disease_ID	Disease name	ICD_11	Uniprot ID	Gene names
T20709	DI0037	Asthma	[ICD-11: CA23]	P08173	CHRM4
T20709	DI0141	Eye anterior segment structural developmental anomaly	[ICD-11: LA11]	P08173	CHRM4
T20709	DI0166	Glaucoma	[ICD-11: 9C61]	P08173	CHRM4
T20709	DI0293	Nausea/vomiting	[ICD-11: MD90]	P08173	CHRM4
T20709	DI0362	Respiratory system disease	[ICD-11: CB40-CB7Z]	P08173	CHRM4
T48873	DI0079	Choreiform disorder	[ICD-11: 8A01]	Q05940	SLC18A2
T48873	DI0125	Dissociative neurological symptom disorder	[ICD-11: 6B60]	Q05940	SLC18A2
T48873	DI0129	Dystonic disorder	[ICD-11: 8A02]	Q05940	SLC18A2
T48873	DI0137	Essential hypertension	[ICD-11: BA00]	Q05940	SLC18A2
T48873	DI0190	Hypertension	[ICD-11: BA00-BA04]	Q05940	SLC18A2
T01777	DI0166	Glaucoma	[ICD-11: 9C61]	P18825	ADRA2C
T01777	DI0190	Hypertension	[ICD-11: BA00-BA04]	P18825	ADRA2C
T01777	DI0196	Hypotension	[ICD-11: BA20-BA21]	P18825	ADRA2C
T01777	DI0308	Obesity	[ICD-11: 5B80-5B81]	P18825	ADRA2C
T01777	DI0310	Ocular disease	[ICD-11: N.A.]	P18825	ADRA2C
T01777	DI0396	Substance abuse	[ICD-11: 6C40]	P18825	ADRA2C
T99799	DI0324	Pain	[ICD-11: MG30-MG3Z]	P06276	BCHE
T99799	DI0411	Tonus and reflex abnormality	[ICD-11: MB47]	P06276	BCHE
T58992	DI0059	Bowel habit change	[ICD-11: ME05]	P41143	OPRD1
T58992	DI0218	Irritable bowel syndrome	[ICD-11: DD91]	P41143	OPRD1
T58992	DI0324	Pain	[ICD-11: MG30-MG3Z]	P41143	OPRD1
T97613	DI0214	Insomnia	[ICD-11: 7A00-7A0Z]	P48039	MTNR1A